Related Experiment Video
Updated: Jul 12, 2025

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins
Daniel J McGrail1, Yang Li2, Roger S Smith3
1Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44106, USA; Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA.
Abstract:
Defects in homologous recombination DNA repair (HRD) both predispose to cancer development and produce therapeutic vulnerabilities, making it critical to define the spectrum of genetic events that cause HRD. However, we found that mutations in BRCA1/2 and other canonical HR genes only identified 10%-20% of tumors that display genomic evidence of HRD. Using a networks-based approach, we discovered that over half of putative genes causing HRD originated outside of canonical DNA damage response genes, with a particular enrichment for RNA-binding protein (RBP)-encoding genes. These putative drivers of HRD were experimentally validated, cross-validated in an independent cohort, and enriched in cancer-associated genome-wide association study loci. Mechanistic studies indicate that some RBPs are recruited to sites of DNA damage to facilitate repair, whereas others control the expression of canonical HR genes. Overall, this study greatly expands the repertoire of known drivers of HRD, with implications for basic biology, genetic screening, and therapy stratification.
Insights
Defects in homologous recombination DNA repair (HRD) are linked to cancer. This study reveals new genes, particularly RNA-binding proteins, that cause HRD beyond BRCA1/2, improving cancer screening and treatment.
Area of Science:
- Genomics
- Molecular Biology
- Cancer Research
Background:
- Defects in homologous recombination DNA repair (HRD) contribute to cancer development and create therapeutic vulnerabilities.
- Mutations in canonical HR genes like BRCA1/2 explain only 10-20% of tumors with genomic HRD.
- A comprehensive understanding of HRD drivers is crucial for cancer diagnostics and therapeutics.
Purpose of the Study:
- To identify novel genetic drivers of homologous recombination DNA repair (HRD) beyond established genes.
- To explore the role of RNA-binding proteins (RBPs) in HRD.
- To expand the repertoire of genes implicated in HRD for improved clinical applications.
Main Methods:
- Utilized a networks-based approach to discover novel HRD-associated genes.
- Experimentally validated putative HRD drivers.
- Cross-validated findings in an independent patient cohort.
- Analyzed enrichment in cancer-associated genome-wide association study (GWAS) loci.
Main Results:
- Over half of identified HRD drivers were outside of canonical DNA damage response genes.
- RNA-binding protein (RBP)-encoding genes were significantly enriched among HRD drivers.
- Validated RBPs function in DNA damage repair or regulate expression of HR genes.
- Identified novel genetic contributors to HRD, expanding beyond BRCA1/2.
Conclusions:
- The study significantly expands the known drivers of homologous recombination DNA repair (HRD).
- RNA-binding proteins represent a critical, previously underappreciated class of HRD genes.
- Findings have implications for genetic screening, basic cancer biology, and therapy stratification.
Related Concept Videos
RNA Splicing
Homologous Recombination
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Base Excision Repair
The first step of...
Fixing Double-strand Breaks
RNA Editing

